Physicochemical Properties
| Molecular Formula | C18H20CL2N2O3 |
| Molecular Weight | 383.27 |
| Exact Mass | 382.085 |
| Elemental Analysis | C, 56.41; H, 5.26; Cl, 18.50; N, 7.31; O, 12.52 |
| CAS # | 107355-45-3 |
| PubChem CID | 441048 |
| Appearance | White to off-white solid powder |
| LogP | 4.294 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 25 |
| Complexity | 440 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | ClC1C=C(C2=NCCO2)C=C(Cl)C=1OCCCCCC1ON=C(C)C=1 |
| InChi Key | JJDHAOLOHQTGMG-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C18H20Cl2N2O3/c1-12-9-14(25-22-12)5-3-2-4-7-23-17-15(19)10-13(11-16(17)20)18-21-6-8-24-18/h9-11H,2-8H2,1H3 |
| Chemical Name | Isoxazole, 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methyl- |
| Synonyms | WIN54954; WIN-54954; WIN 54954; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | For 50 out of 52 rhinovirus serotypes, WIN 54954 decreases plaque formation (MICs range from 0.007 to 2.2 μg/mL)[1]. WIN 54954 has an EC80 of 0.06 μg/mL and inhibits 15 frequently identified enteroviruses[1]. |
| ln Vivo | At doses of 2 and 100 mg/kg, respectively, WIN 54954 (2-100 mg/kg; po) prevents 50% of the mice from becoming paralyzed after contracting coxsackievirus A-9 and echovirus-9[1]. |
| References |
[1]. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74. [2]. Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules. 2011 Oct 11;16(10):8475-503. |
| Additional Infomation |
WIN54954 is an aromatic ether. WIN-54954 is a broad-spectrum antipicornavirus drug. |
Solubility Data
| Solubility (In Vitro) | DMSO : 100 mg/mL (260.91 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6091 mL | 13.0456 mL | 26.0913 mL | |
| 5 mM | 0.5218 mL | 2.6091 mL | 5.2183 mL | |
| 10 mM | 0.2609 mL | 1.3046 mL | 2.6091 mL |